Name: Metalyse® - Administration | Boehringer Ingelheim Finland
Keywords: Administration

Single IV bolus administration

Metalyse® 25 mg is administered by a single IV bolus over 5 to 10 seconds, eliminating the need for a one-hour infusion, as required for Actilyse®^2-3

Metalyse® 25 mg comes as one single vial of powder for
reconstitution
The dosing for Metalyse® 25 mg is simple with 5
weight-based tiers:

Weight (kg)	Corresponding volume of reconstituted solution (ml)	Tenecteplase (Units)	Tenecteplase (mg)
< 60	3	3000	15
≥ 60 to < 70	3.5	3500	17.5
≥ 70 to < 80	4	4000	20
≥ 80 to <90	4.5	4500	22.5
≥ 90	5	5000	25

Click here for additional information on reconstitution

Why is Metalyse® 25 mg quicker
and easier to use compared to
Actilyse®?

Tenecteplase is a genetically modified version of alteplase. Mutations in the protein sequence increased the specificity of Metalyse® (Tenecteplase) to fibrin and made it more resistant to natural inhibitors, which increased its half-life and allowed for shorter treatment duration.

Footnotes

†
Tenecteplase was administrated within 4.5 hours after onset of stroke symptoms, as a one-time decile-weight-tiered bolus dose, based on 0.25 mg/kg by 10 kg steps, for the maximum weight at each tier: < 60 kg, 15 mg tenecteplase; ≥ 60 to < 70 kg, 17.5 mg; ≥ 70 to < 80 kg, 20 mg; ≥ 80 to < 90 kg, 22.5 mg; and ≥ 90 kg, 25 mg.
‡
10% bolus over 1 minute, the remainer infused over 60 minutes.⁶
§
One time 5 second bolus.⁶

References

Metalyse® European Summary of Product Characteristics.
Menon BK, et al. Lancet 2022; 400:161-169.
Bivard A, et al. Lancet Neurol. 2022; 21:520-27.
Actilyse® European Summary of Product Characteristics.
Dancsecs K. A. et al. Am J Emerg Med. 2021; 47:90-94.
Miller, SE and Warach, SJ. Neurotherapeutics 2023; 20:664–678.
Zhu A, et al. Res Pract Thromb Haemost. 2022; 6:e12795.

Metalyse®